Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dwarfism
Biotech
Ascendis' dwarfism drug hits in phase 3, threatens BioMarin
Ascendis reported phase 3 growth disorder data that exceeded analyst expectations and positions the biotech to file for approval next year.
Nick Paul Taylor
Sep 17, 2024 9:36am
Sanofi will drop dwarfism drug as part of rare disease clear-out
Jul 25, 2024 7:58am
BridgeBio posts BioMarin-beating data on dwarfism drug prospect
Jun 4, 2024 7:30am
Drug lengthens limb bones in Robinow syndrome
Feb 17, 2023 4:01pm
Gene therapy player InnoSkel debuts with €20M
Dec 14, 2020 8:50am
BioMarin nabs FDA review for dwarfism drug vosoritide
Nov 4, 2020 9:52am
